文献速递头颈与中枢神经肿瘤

创新胶质母细胞瘤治疗个体化筛选试验首批结果:一项采用贝叶斯适应性随机化的新诊断胶质母细胞瘤II期平台试验

Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization.
PubMed 文献 · J Clin Oncol · 2023-09-18

INSIGhT是一项采用反应适应性随机化和基因组分析的II期平台试验,同时评估阿贝西利、来那替尼和CC-115对照共同对照组。237例新诊断MGMT未甲基化胶质母细胞瘤患者中,阿贝西利和来那替尼耐受良好,CC-115组58%出现≥3级治疗相关毒性;阿贝西利和来那替尼无进展生存期显著优于对照组,但无总生存获益。

要点

  • 阿贝西利组PFS显著优于对照组(HR 0.72,95%CI 0.49-1.06,单侧P=.046)
  • 来那替尼组PFS显著优于对照组(HR 0.72,95%CI 0.50-1.02,单侧P=.033)
  • CC-115组58%患者出现≥3级治疗相关毒性,无PFS获益(单侧P=.523)

核心结论

  • INSIGhT设计通过共享对照组和适应性随机化实现了三种实验药物的高效同时测试。
  • 两个实验组无进展生存期优于对照组,但均未显示总生存获益。
  • INSIGhT设计可能促进胶质母细胞瘤更高效的治疗发现,试验已添加新组。

研究设计与样本

  • II期平台试验,采用反应适应性随机化和基因组分析,同时评估三种实验药物对照共同对照组。
  • 纳入新诊断O6-甲基鸟嘌呤-DNA甲基转移酶未甲基化胶质母细胞瘤患者,需有肿瘤基因分型以识别优势信号通路(EGFR、磷脂酰肌醇3-激酶和CDK)的预设生物标志物亚群。
  • 初始随机分配为对照组(放疗联合替莫唑胺)与实验组1:1:1:1,后续基于生物标志物特异性无进展生存数据采用贝叶斯适应性随机化。
  • 主要终点为总生存期,报告单侧P值,试验注册号NCT02977780。
  • 2017-2021年共治疗237例患者(对照组71例;阿贝西利组73例;来那替尼组81例;CC-115组12例)。

主要发现

  • 阿贝西利和来那替尼耐受良好,CC-115与58%患者出现≥3级治疗相关毒性相关。
  • 阿贝西利组无进展生存期显著优于对照组(HR 0.72,95%CI 0.49-1.06,单侧P=.046)。
  • 来那替尼组无进展生存期显著优于对照组(HR 0.72,95%CI 0.50-1.02,单侧P=.033)。
  • CC-115组无进展生存期无获益(单侧P=.523)。
  • 所有实验治疗均未显示显著总生存获益(P>.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial that uses response adaptive randomization and genomic profiling to efficiently identify novel therapies for phase III testing. Three initial experimental arms (abemaciclib [a cyclin-dependent kinase [CDK]4/6 inhibitor], neratinib [an epidermal growth factor receptor [EGFR]/human epidermal growth factor receptor 2 inhibitor], and CC-115 [a deoxyribonucleic acid-dependent protein kinase/mammalian target of rapamycin inhibitor]) were simultaneously evaluated against a common control arm. We report the results for each arm and examine the feasibility and conduct of the adaptive platform design. PATIENTS AND METHODS: Patients with newly diagnosed O6-methylguanine-DNA methyltransferase-unmethylated glioblastoma were eligible if they had tumor genotyping to identify prespecified biomarker subpopulations of dominant glioblastoma signaling pathways (EGFR, phosphatidylinositol 3-kinase, and CDK). Initial random assignment was 1:1:1:1 between control (radiation therapy and temozolomide) and the experimental arms. Subsequent Bayesian adaptive randomization was incorporated on the basis of biomarker-specific progression-free survival (PFS) data. The primary end point was overall survival (OS), and one-sided P values are reported. The trial is registered with ClinicalTrials.gov (identifier: NCT02977780). RESULTS: Two hundred thirty-seven patients were treated (71 control; 73 abemaciclib; 81 neratinib; 12 CC-115) in years 2017-2021. Abemaciclib and neratinib were well tolerated, but CC-115 was associated with ≥ grade 3 treatment-related toxicity in 58% of patients. PFS was significantly longer with abemaciclib (hazard ratio [HR], 0.72; 95% CI, 0.49 to 1.06; one-sided P = .046) and neratinib (HR, 0.72; 95% CI, 0.50 to 1.02; one-sided P = .033) relative to the control arm but there was no PFS benefit with CC-115 (one-sided P = .523). None of the experimental therapies demonstrated a significant OS benefit (P > .05). CONCLUSION: The INSIGhT design enabled efficient simultaneous testing of three experimental agents using a shared control arm and adaptive randomization. Two investigational arms had superior PFS compared with the control arm, but none demonstrated an OS benefit. The INSIGhT design may promote improved and more efficient therapeutic discovery in glioblastoma. New arms have been added to the trial.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rahman R, Trippa L, Lee EQ, et al. Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. J Clin Oncol. 2023. PMID: 37722087. doi:10.1200/JCO.23.00493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。